PKOH vs RIGL Comparison

Park-Ohio Holdings Corp is a diversified international company offering its clients supply chain management outsourcing services, capital equipment used on their production lines, and manufactured components used to assemble their products. The company operates through three reportable segments: Supply Technologies, Assembly Components, and Engineered Products. Maximum revenue is generated from the Supply Technologies segment, which is mainly engaged in sourcing, planning, and procurement of several production components, including fasteners, pins, nuts, bolts, valves, hoses, wire harnesses, clamps and fittings, etc. Geographically, the company generates maximum revenue from its business in the United States, followed by Europe, Asia, Mexico, Canada, and other regions.

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.